Yen Kristen's Form 4 filing
Soleno Therapeutics IncSLNO · filed Aug 7, 2024
- Accession no.
- 0001415889-24-020946
- Filed
- Aug 7, 2024
- Trade date
- Aug 5-6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $500.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yen KristenCIK 0001643441 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2024 | Common Stock | SSaleDisposed | −2,826 | $45.48F2 | −$128,526.48 | 103,426 | Direct | |
| Aug 5, 2024 | Common Stock | SSaleDisposed | −2,191 | $46.14F4 | −$101,092.74 | 101,235 | Direct | |
| Aug 6, 2024 | Common Stock | SSaleDisposed | −585 | $43.64F5 | −$25,529.4 | 100,650 | Direct | |
| Aug 6, 2024 | Common Stock | SSaleDisposed | −1,976 | $45.25F6 | −$89,414 | 98,674 | Direct | |
| Aug 6, 2024 | Common Stock | SSaleDisposed | −3,396 | $45.89F7 | −$155,842.44 | 95,278 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $44.87 to $45.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $45.87 to $46.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $43.245 to $44.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $44.66 to $45.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $45.66 to $46.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer title: Senior Vice President, Clinical Operations